Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab in MSS colorectal cancer
ChiCTR2100051724Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by The Second Affiliated Hospital of Fujian Medical University. Primary endpoint: Objective Response Rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051724.